Underrepresentation of Older Adults in Clinical Trials of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hematologic Malignancies: An FDA Analysis

被引：0

作者：

Seam, Pamela ^{[1
]}

Mahat, Upendra ^{[2
]}

Bouchkouj, Najat ^{[2
]}

Sharma, Poornima ^{[2
]}

Peredo-Pinto, Helka ^{[2
]}

Elmacken, Mona ^{[2
]}

Kaushal, Megha ^{[2
]}

Jia, Yuxia ^{[2
]}

Wang, Shu ^{[3
]}

Xu, Zhiheng ^{[3
]}

Kasamon, Yvette ^{[1
]}

Kanaparu, Bindu ^{[1
]}

Richardson, Nicholas ^{[1
]}

Gormley, Nicole ^{[1
]}

机构：

[1] US FDA, Div Hematol Malignancies 2, Ctr Drug Evaluat & Res CDER, Silver Spring, MD USA

[2] US FDA, Div Clin Evaluat Hematol, Ctr Biol Evaluat & Res CBER, Off Therapeut Prod OTP, Silver Spring, MD USA

[3] US FDA, Ctr Drug Evaluat & Res CDER, Off Biostat, Silver Spring, MD USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-186544

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
Marco L. Davila
Diana C. G. Bouhassira
Jae H. Park
Kevin J. Curran
Eric L. Smith
Hollie J. Pegram
Renier Brentjens
International Journal of Hematology, 2014, 99 : 361 - 371
[42] Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
Davila, Marco L.
Bouhassira, Diana C. G.
Park, Jae H.
Curran, Kevin J.
Smith, Eric L.
Pegram, Hollie J.
Brentjens, Renier
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (04) : 361 - 371
[43] Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
Polgarova, Kamila
Otahal, Pavel
Salek, Cyril
Pytlik, Robert
FRONTIERS IN ONCOLOGY, 2022, 12
[44] Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Gill, Saar
June, Carl H.
IMMUNOLOGICAL REVIEWS, 2015, 263 (01) : 68 - 89
[45] Chimeric Antigen Receptor T Cells in Hematologic Malignancies
Shank, Brandon R.
Do, Bryan
Sevin, Adrienne
Chen, Sheree E.
Neelapu, Sattva S.
Horowitz, Sandra B.
PHARMACOTHERAPY, 2017, 37 (03): : 334 - 345
[46] Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) Therapy
Figura, N.
Jain, M.
Sim, A.
Dean, E.
Balagurunathan, Y.
Chavez, J.
Shah, B.
Khimani, F.
Lazaryan, A.
Davila, M.
Liu, H.
Kim, S.
Locke, F.
Robinson, T.
RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S311 - S312
[47] Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Dhawale, Tejaswini
Johnson, P. Connor
Boateng, Kofi
Barata, Anna
Traeger, Lara
Nelson, Ashley M.
Lavoie, Mitchell W.
Holmbeck, Katherine
Choe, Joanna
Nabily, Anisa
Tripathi, Astha
Amonoo, Hermioni L.
Frigault, Matt
El-Jawahri, Areej
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (04): : 402.e1 - 402.e12
[48] Lymphapheresis Yields in the Production of Chimeric Antigen Receptor (CAR) T-Cell Therapy
Allen, E. S.
Cantilena, C.
TRANSFUSION, 2015, 55 : 102A - 103A
[49] Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy
Choi, Gyeyoung
Shin, Gyeongseon
Bae, SeungJin
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (19)
[50] Critical care considerations of chimeric antigen receptor (CAR) T-cell therapy
Ponnapalli, Anoosha
Arora, Avneet Kaur
Soubani, Ayman O.
RESPIRATORY MEDICINE, 2025, 238

← 1 2 3 4 5 →